Adma Biologics Inc
Adma Biologics Inc (ADMA) Covered Calls
Adma Biologics Inc trades in the Biotechnology industry with an IV Rank of 42.46%, average versus the past year. ADMA's highest covered call setup is the $17.00 strike expiring Jan 15, 2027, sorted by theoretical annualized return. It's 29.08% out of the money with 56 days to expiration, a 29.46% return until expiration, and a 192.02% theoretical annualized return. Across the setups shown, annualized returns run from 15.68% to 192.02% at strikes between $14.00 and $20.00, with 28 to 427 days to expiration, as of Nov 20, 2026.
Read more
Running ADMA covered calls helps you generate income from Adma Biologics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ADMA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ADMA stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ADMA covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ADMA covered call is worth writing.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S.
| 2027-01-15 | 56 | 17.00 | 29.08 | 0.05 | 0.70 | 388.00 | 29.46 | 192.02 | -0.38 | +0.21 | 646 | 0.65 |
| 2026-12-18 | 28 | 14.00 | 6.30 | 0.35 | 1.40 | 118.00 | 8.96 | 116.80 | -2.66 | +0.44 | 399 | 1.05 |
| 2028-01-21 | 427 | 20.00 | 51.86 | 0.95 | 3.00 | 778.00 | 59.07 | 50.50 | -7.21 | +0.42 | 375 | 2.05 |
| 2028-01-21 | 427 | 17.00 | 29.08 | 1.60 | 2.50 | 543.00 | 41.23 | 35.24 | -12.15 | +0.47 | 188 | 0.90 |
| 2027-05-21 | 182 | 15.00 | 13.90 | 0.40 | 2.55 | 223.00 | 16.93 | 33.96 | -3.04 | +0.47 | 60 | 2.15 |
| 2028-01-21 | 427 | 15.00 | 13.90 | 2.05 | 3.60 | 388.00 | 29.46 | 25.18 | -15.57 | +0.57 | 439 | 1.55 |
| 2027-05-21 | 182 | 14.00 | 6.30 | 0.20 | 2.95 | 103.00 | 7.82 | 15.68 | -1.52 | +0.52 | 22 | 2.75 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank42.46% Moderate
- Market cap (M$)2,922
- 52 weeks high-35.63%
- 52 weeks low82.66%
- Analyst recommendationBuy
1.75 - Target price$18.00
36.67% above the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2026-11-04
- P/E16.96
- Future P/E14.63
- EPS (ttm)0.78
- EPS growth next 5 years20.09%
As of Nov 20, 2026